好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A randomized, placebo-controlled, double-blind, Phase 1b/2 study of the novel anti-myostatin adnectin RG6206 (BMS-986089) in ambulatory boys with Duchenne muscular dystrophy
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - (-)
431
Authors/Disclosures
Kathryn R. Wagner, MD, PhD (The Kennedy Krieger Institute)
PRESENTER
Dr. Wagner has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. Wagner has stock in F. Hoffmann-La Roche.
Brenda L. Wong, MD (University of Massachusetts Medical School) No disclosure on file
Barry Byrne Barry Byrne has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Barry Byrne has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rocket Pharma. Barry Byrne has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Muscular Dystrophy Association.
No disclosure on file
No disclosure on file
Joshua Tam, MD, PhD (Princess Alexandra Hospital) No disclosure on file
Michael Rabbia No disclosure on file
Jeppe Buchbjerg, PhD No disclosure on file
No disclosure on file
Clifford Bechtold No disclosure on file